U.S. doubles annual Malawi HIV/AIDS support to $45 million

NewsGuard 100/100 Score

The U.S. government recently announced a commitment to double its support for Malawi's efforts to fight HIV/AIDS to $45 million annually, Xinhua reports (Xinhua, 6/2).

The "Partnership Framework" was established after U.S. Ambassador to Malawi Peter Bodde and Malawi's Secretary to the Treasury Randson Mwadiwa signed a "landmark document" on May 18 that sets the foundation for a new framework for the U.S.-Malawi collaboration to combat HIV/AIDS, according to a statement from the U.S. Embassy in Malawi.

The document calls for "increased focus on reducing new HIV infections, while maintaining ongoing activities aimed at improving the quality of treatment and care and mitigating the impacts on individuals and households," according to the release, which adds that objectives should be achieved within a context of "enhanced Malawian leadership and ownership of the overall response."

At the signing of the partnership, Bodde said the framework with Malawi "will serve as the model for those that follow in other countries" (Embassy of the U.S., Lilongwe, Malawi release). 

Malawi is the first country to sign an agreement with the U.S. following the 2008 reauthorization of PEPFAR. According to Xinhua, about 200,000 HIV-positive people in Malawi are receiving free antiretroviral treatments. There are about one million people living with HIV/AIDS in the country (Xinhua, 6/2).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk